Roche Holding AG (VIE:ROGP)
Austria · Delayed Price · Currency is EUR | Market Cap | 301.98B +36.0% |
| Revenue (ttm) | 68.20B -0.8% |
| Net Income | 13.37B +30.9% |
| EPS | 16.61 +30.6% |
| Shares Out | n/a |
| PE Ratio | 22.59 |
| Forward PE | 16.85 |
| Dividend | 10.85 (2.85%) |
| Ex-Dividend Date | Mar 12, 2026 |
| Volume | n/a |
| Open | 384.00 |
| Previous Close | 380.00 |
| Day's Range | 381.00 - 385.00 |
| 52-Week Range | 270.80 - 411.10 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 22, 2026 |
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavir... [Read more]
Financial Performance
In 2025, Roche Holding AG's revenue was 63.36 billion, an increase of 1.54% compared to the previous year's 62.40 billion. Earnings were 12.88 billion, an increase of 55.61%.
Financial numbers in CHF Financial StatementsNews
CHMP recommends EU approval of Roche’s Ocrevus for children and adolescents
Roche (RHHBY) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of Ocrevus intravenous infusion for the treatment of pediatric ...
CHMP recommends EU approval of Roche's Ocrevus for children and adolescents with relapsing multiple sclerosis
Basel, 18 September 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the appro...
Genentech and Roche Announce Grand Opening of Boston R&D Innovation Center
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $RHHBY--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), today celebrated the grand opening of the Roche Genentech Innovation Cente...
Roche announces grand opening of its Innovation Center Boston to drive advancements in Cardiovascular, Renal and Metabolic diseases
Basel, 17 September 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today the grand opening of the Roche Genentech Innovation Center Boston, expanding Roche and Genentech's US research presence in...
Genentech reports CELESTIMO study meets primary endpoint
Genentech, a member of Roche (RHHBY), announced that the Phase III CELESTIMO study evaluating Lunsumio in combination with lenalidomide versus Rituxan plus lenalidomide in people with relapsed or refr...
Roche's Lunsumio-based regimen significantly improves progression-free survival in follicular lymphoma in phase III CELESTIMO study
Basel, 17 September 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the phase III CELESTIMO study evaluating Lunsumio® (mosunetuzumab) in combination with lenalidomide versus MabThera®/...
Genentech's Lunsumio-Based Regimen Significantly Improves Progression-Free Survival in Follicular Lymphoma in Phase III CELESTIMO Study
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that the Phase III CELESTIMO study evaluating Lunsumio® (mosunetuzuma...
Roche announces MediLink’s phase III trial of Tam-Peli met primary endpoint
Roche (RHHBY) announced that its collaborator MediLink released interim results from the randomised phase III TAISHAN-302 trial evaluating Tam-Peli versus topotecan in Chinese patients with relapsed s...
Roche's collaborator MediLink announces phase III data for Tam-Peli showing significantly improved overall survival in Chinese patient population with relapsed small-cell lung cancer
Basel, 13 September 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) today announced that its collaborator MediLink released interim results from the randomised phase III TAISHAN-302 trial evaluating Tam-Pel...
Roche price target raised to CHF 380 from CHF 365 at HSBC
HSBC raised the firm’s price target on Roche (RHHBY) to CHF 380 from CHF 365 and keeps a Hold rating on the shares. The firm adjusted targets in the healthcare…
Genentech granted Priority Review for Enspryng sBLA
Genentech, a member of Roche (RHHBY), announced that the FDA has granted Priority Review to a supplemental biologics license application, or sBLA, for Enspryng for the treatment of myelin oligodendroc...
U.S. FDA Grants Priority Review for Genentech's Enspryng for MOGAD, an Autoimmune Disease With No Approved Treatments
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--FDA filing acceptance announced for Enspryng (satralizumab) in MOGAD, a rare neurological disease.
U.S. FDA grants Priority Review for Roche's Enspryng for MOGAD, an autoimmune disease with no approved treatments
Basel, 10 September 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has granted Priority Review to a supplemental Biologics License Applicati...
Roche initiated with an Outperform at RBC Capital
RBC Capital initiated coverage of Roche (RHHBY) with an Outperform rating and CHF 400 price target The near-to-mid-term the base business is gaining momentum, while the pipeline “offers deeper potenti...
Treeline Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate TLN-121 in Combination with CD20xCD3 T-Cell-Engaging Bispecific Antibodies
WATERTOWN, Mass.--(BUSINESS WIRE)--Treeline Biosciences, Inc. (“Treeline”) today announced a clinical trial collaboration and supply agreement with Roche (SIX: RO, ROP; OTCQX: RHHBY) to evaluate TLN-1...
H.C. Wainwright says Novartis success in RMS trials does not impact TG’s Briumvi
After Novartis (NVS) announced topline data from the REMODEL-1/-2 trials of remibrutinib in relapsing multiple sclerosis, H.C. Wainwright analyst Emily Bodnar believes that remibrutinib will be favore...
Roche signs global licensing pact for Simcere's experimental blood cancer drug
Switzerland's Roche will pay $75 million upfront to Simcere Pharmaceutical Group for rights to an experimental blood cancer drug, the Chinese drugmaker said Tuesday.
mRNA immunotherapy discontinuation a negative for BioNTech, says Morgan Stanley
After BioNTech (BNTX) announced the discontinuation of its Phase 2 study partnered with Roche (RHHBY) of autogene cevumeran, an individualized mRNA immunotherapy, or cancer vaccine, in adjuvant colore...
Roche announces new two-year data from Phase IIIb/IV SALWEEN study
Roche (RHHBY) announced new two-year data from the Phase IIIb/IV SALWEEN study of Vabysmo, presented at the 19th Asia-Pacific Vitreo-retina Society Congress in Australia. The results showed significan...
Roche receives FDA approval for companion diagnostic tests for Ziihera
Roche (RHHBY) announced that it has received FDA approval for expanded use of its PATHWAY HER2 and VENTANA HER2 Dual ISH DNA Probe Cocktail tests. “These companion diagnostics are now…
Roche receives FDA approval for companion diagnostic tests to identify patients with HER2-positive metastatic gastroesophageal adenocarcinoma eligible for ZIIHERA
The PATHWAY HER2 (4B5) test and VENTANA HER2 Dual ISH DNA Probe Cocktail help identify HER2-positive metastatic gastric, gastroesophageal junction and esophageal adenocarcinoma. Differential diagnosis...
FDA Clears Roche And Eli Lilly's Alzheimer's Blood Test
The Food and Drug Administration has cleared a new blood test from Roche and Eli Lilly designed to help identify symptoms related to Alzheimer's disease in patients over age 55, Roche said on Monday m...
FDA Approves Alzheimer's Blood Test Developed by Roche and Eli Lilly
The Food and Drug Administration cleared a blood test for identifying Alzheimer's disease symptoms, which was developed by Roche and Eli Lilly.
Roche, Eli Lilly's Alzheimer's blood test gets FDA clearance
The U.S. Food and Drug Administration has cleared Roche and partner Eli Lilly's blood test to help identify signs of Alzheimer's disease in people aged 55 and older with cognitive decline.
Labcorp to offer Elecsys pTau-217 test for Alzheimer’s disease
Labcorp (LH) announced it will offer the Elecsys pTau-217 test following clearance by the U.S. FDA. Developed by Roche Diagnostics (RHHBY), the blood test aids in identifying amyloid pathology associa...